摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-Butyl (4-bromo-3-hydroxybenzyl)carbamate | 916213-63-3

中文名称
——
中文别名
——
英文名称
tert-Butyl (4-bromo-3-hydroxybenzyl)carbamate
英文别名
tert-butyl N-[(4-bromo-3-hydroxyphenyl)methyl]carbamate
tert-Butyl (4-bromo-3-hydroxybenzyl)carbamate化学式
CAS
916213-63-3
化学式
C12H16BrNO3
mdl
——
分子量
302.168
InChiKey
CRRHIODJGDCGPG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • Heterobicyclic metalloprotease inhibitors
    申请人:Steeneck Christoph
    公开号:US20070155738A1
    公开(公告)日:2007-07-05
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • Heterobicyclic Metalloprotease Inhibitors
    申请人:STEENECK Christoph
    公开号:US20090312312A1
    公开(公告)日:2009-12-17
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • HETEROBICYCLIC METALLOPROTEASE INHIBITORS
    申请人:Steeneck Christoph
    公开号:US20120015920A1
    公开(公告)日:2012-01-19
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • US7795245B2
    申请人:——
    公开号:US7795245B2
    公开(公告)日:2010-09-14
  • [EN] HETEROBICYCLIC METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASE HETEROBICYCLIQUE
    申请人:ALANTOS PHARMACEUTICALS INC
    公开号:WO2006128184A2
    公开(公告)日:2006-11-30
    [EN] The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.
    [FR] La présente invention concerne d'une manière générale des agents pharmaceutiques contenant un groupe amide et, en particulier, des composés inhibiteurs de métalloprotéase hétérobicyclique contenant un amide. Cette invention concerne plus particulièrement une nouvelle classe de composés inhibiteurs MMP-13 hétérobicycliques qui présente une puissance améliorée par rapport aux inhibiteurs MMP- 13 connus jusqu'à présent.
查看更多